NZ588467A - Modified chaperonin 10 (CPN10) polypeptides and pattern recognition receptor (PRR) signalling - Google Patents

Modified chaperonin 10 (CPN10) polypeptides and pattern recognition receptor (PRR) signalling

Info

Publication number
NZ588467A
NZ588467A NZ588467A NZ58846709A NZ588467A NZ 588467 A NZ588467 A NZ 588467A NZ 588467 A NZ588467 A NZ 588467A NZ 58846709 A NZ58846709 A NZ 58846709A NZ 588467 A NZ588467 A NZ 588467A
Authority
NZ
New Zealand
Prior art keywords
polypeptides
cpn10
prr
signalling
pattern recognition
Prior art date
Application number
NZ588467A
Inventor
Dean Jason Naylor
Richard James Brown
Christopher Bruce Howard
Linda Alisson Ward
Jeanette Elizabeth Stok
Andrew Leigh James
Daniel Scott Lambert
Kylie Jane Ralston
Heumen Walter Rene Antonius Van
Bakker Christopher John De
Original Assignee
Cbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2008/000520 external-priority patent/WO2009124333A1/en
Priority claimed from AU2009900613A external-priority patent/AU2009900613A0/en
Application filed by Cbio Ltd filed Critical Cbio Ltd
Publication of NZ588467A publication Critical patent/NZ588467A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)

Abstract

Disclosed are isolated Cpn10 polypeptides possessing an increased affinity for a PRR ligand compared to Ala Cpn10 polypeptide. In a further embodiment, the present invention also relates to modified chaperonin 10 polypeptides, and to nucleic acids encoding the same and to compositions comprising such polypeptides and uses thereof.
NZ588467A 2008-04-11 2009-04-09 Modified chaperonin 10 (CPN10) polypeptides and pattern recognition receptor (PRR) signalling NZ588467A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/AU2008/000520 WO2009124333A1 (en) 2008-04-11 2008-04-11 Modified chaperonin 10 and prr signaling
AU2009900613A AU2009900613A0 (en) 2009-02-13 Modified Cpn10 and PRR signalling
PCT/AU2009/000444 WO2009124353A1 (en) 2008-04-11 2009-04-09 Modified cpn10 and prr signalling

Publications (1)

Publication Number Publication Date
NZ588467A true NZ588467A (en) 2012-11-30

Family

ID=41161469

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588467A NZ588467A (en) 2008-04-11 2009-04-09 Modified chaperonin 10 (CPN10) polypeptides and pattern recognition receptor (PRR) signalling

Country Status (12)

Country Link
US (1) US9234019B2 (en)
EP (1) EP2265635A4 (en)
JP (1) JP2011519548A (en)
KR (1) KR20110005710A (en)
CN (1) CN102015757B (en)
AU (1) AU2009235953B2 (en)
BR (1) BRPI0911676A2 (en)
CA (1) CA2720617A1 (en)
MX (1) MX2010011169A (en)
NZ (1) NZ588467A (en)
RU (1) RU2010145972A (en)
WO (1) WO2009124353A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102711793A (en) * 2009-10-09 2012-10-03 悉生物有限公司 Chaperonin 10 variants
MX347515B (en) * 2010-04-01 2017-04-28 Oncomed Pharmaceuticals Inc * Frizzled-binding agents and uses thereof.
EP2490021A1 (en) * 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684578B2 (en) 1993-11-30 1997-12-18 University Of Queensland, The Antagonists to chaperonin 10
CN100406891C (en) * 2001-06-27 2008-07-30 詹森药业有限公司 EPF receptor assays, compounds and therapeutic compsns.
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
ATE548047T1 (en) * 2004-01-16 2012-03-15 Cbio Ltd CHAPERONIN-10 MODULATION OF GREAT RECEPTOR-INDUCABLE CYTOKINE AND CHEMOKINE SECRETION
MX2008000596A (en) * 2005-07-11 2008-03-19 Cbio Ltd Chaperonin 10-induced immunomodulation.
EP1937723B1 (en) * 2005-08-31 2013-11-13 Invion Limited Modified chaperonin 10
EP1951282A4 (en) * 2005-10-20 2009-09-02 Cbio Ltd Treatment of hypersensitivity

Also Published As

Publication number Publication date
JP2011519548A (en) 2011-07-14
KR20110005710A (en) 2011-01-18
WO2009124353A1 (en) 2009-10-15
MX2010011169A (en) 2011-03-01
BRPI0911676A2 (en) 2016-11-29
RU2010145972A (en) 2012-05-20
US9234019B2 (en) 2016-01-12
EP2265635A1 (en) 2010-12-29
WO2009124353A8 (en) 2009-12-30
CA2720617A1 (en) 2009-10-15
US20110082073A1 (en) 2011-04-07
AU2009235953A1 (en) 2009-10-15
CN102015757A (en) 2011-04-13
EP2265635A4 (en) 2013-02-20
AU2009235953B2 (en) 2014-10-02
CN102015757B (en) 2015-12-02

Similar Documents

Publication Publication Date Title
ATE462003T1 (en) CANCER ANTIGEN PEPTIDES DERIVED FROM WT1
PH12013501101B1 (en) Immunosuppressive polypeptides and nucleic acids
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
MX348286B (en) Variant activin receptor polypeptides and uses thereof.
WO2004080148A3 (en) Novel nucleic acids and polypeptides
DK1265914T3 (en) WNT-1-related polypeptides and nucleic acids encoding the same
SG170086A1 (en) Modified molecules which promote hematopoiesis
TW200619228A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
DE69928658D1 (en) BASB029 POLYNUCLEOTIDE AND POLYPEPTIDE FROM NEISSERIA MENINGITIS
WO2010086294A3 (en) Pan-dr binding polypeptides and uses thereof
WO2004087874A3 (en) Novel nucleic acids and polypeptides
NZ588467A (en) Modified chaperonin 10 (CPN10) polypeptides and pattern recognition receptor (PRR) signalling
WO2008087224A3 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
WO2005086654A3 (en) Self-cleaving affinity tags and methods of use
MXPA03006218A (en) Type 2 ctokine receptor and nucleic acids encoding same.
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
WO2005049806A3 (en) Novel nucleic acids and polypeptides
AU2003239659A8 (en) Peptide epitopes common to antigens of the same multigene family
ATE270332T1 (en) POLYNUCLEOTIDE AND POLYPEPTIDE BASB033 FROM NEISSERIA MENINGITIDIS AND USES THEREOF
DE602005016417D1 (en) NEW POLYPEPTIDES FOR IN VINTRO INSULATION AND PREVENTION OF INFECTIONS WITH LEGIONELLA PNEUMOPHILA
EP2666783A3 (en) Compositions and methods for inhibiting interleukin-23 pathways
HK1131162A1 (en) Cytokine derivatives
WO2004041859A3 (en) Peptide fragments of the harp factor inhibiting angiogenesis
WO2009079566A3 (en) Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
WO2006123157A3 (en) Nematistatic protein

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 APR 2016 BY CPA GLOBAL

Effective date: 20130704

LAPS Patent lapsed